ArticleClinical rheumatology2026
Unveiling dry eye with autoimmune features (DEAF): insights from a prospective longitudinal study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDry eye is a prevalent condition that commonly occurs with autoimmune diseases such as Sjögren's disease (SjD). However, some individuals with dry eye were observed to display unique features suggesting an underlying autoimmune process while failing to meet the criteria for a definitive diagnosis of any connective tissue diseases (CTDs). This study aims to describe and propose a novel concept "dry eye with autoimmune features (DEAF)" to define these patients, whose status might suggest a pre-stage of SjD or another unidentified autoimmune condition.
methodsWe conducted a prospective longitudinal study in the ophthalmology clinic by continuously collecting patients with dry eye. The patients' medical history was reviewed, and the ocular examinations and extensive serology tests were conducted. In the discovery cohort, patients were randomized and clustered automatically into three groups through heatmap, PCA, and PLS-DA analysis. We defined the groups as healthy controls with dry eye symptoms (dry eye) group, dry eye patients with autoimmune features (DEAF) group, and Sjögren's disease (SjD) group according to their different characteristics. Based on the summarized characteristics, a validation cohort was subsequently extended. We analyzed clinical and serological parameters and followed up DEAF patients for 3 years to monitor the development of any new onset of CTD.
resultsIn the discovery cohort of 33 dry eye patients, the heatmap, PCA, and PLS-DA clustering revealed distinct features among the three groups. In the validation cohort of 59 patients, 12 were classified into the dry eye group, 28 were in the DEAF group, and 19 were in the SjD group. DEAF patients showed higher DEQ-5 and SPEED scores but lower IgG levels compared to SjD. Total OSS score was observed with no difference among the three groups, while nasal OSS level was higher than temporal conjunctive in the DEAF and SjD groups. DEAF patients showed a trend toward lower total lymphocyte and CD4
conclusionThis study unveiled DEAF patients with significant distinctions in clinical features and serological markers. DEAF may constitute a distinct phase or entity within the autoimmune spectrum, underscoring the intricate nature of autoimmune pathogenesis. Besides, this revelation may bridge the gap between idiopathic dry eye and CTDs. However, these findings are limited to one Chinese cohort, which necessitate multiethnic validation. Keypoints • Patients with dry eye with autoimmune features (DEAF) have significant distinctions in clinical features and serological markers, compared to simple dry eye and Sjögren's disease patients. • DEAF patients may have a higher likelihood of developing connective tissue diseases (CTDs) in the future. • The proposition of DEAF could benefit dry eye patients who have underlying autoimmune disorders in terms of early diagnosis and treatment.
Indexed as
Identifiers
41528637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.